FDC Reports Strong Financial Results for Q1 FY25, Indicating Positive Trend.

FDC, a midcap pharmaceutical company, has recently announced its financial results for the quarter ending June 2024. The company has shown a positive performance in this quarter, with its score improving from 0 to 14 in the last 3 months.

One of the key highlights of FDC’s financials is the growth in its Profit Before Tax less Other Income (PBT) which has increased by 82.3% to Rs 134.29 crore compared to the average PBT of the previous four quarters which was Rs 73.65 crore. This indicates a very positive trend in the near term for the company.

Similarly, the Profit After Tax (PAT) has also shown a significant growth of 56.0% to Rs 119.04 crore compared to the average PAT of the previous four quarters which was Rs 76.31 crore. This further strengthens the positive trend in the near term for FDC.

The company’s Net Sales for this quarter have also been the highest in the last five quarters at Rs 638.27 crore, showing a positive trend in the near term. The Net Sales have also grown by 31.4% compared to the average Net Sales of the previous four quarters which was Rs 485.74 crore.

FDC’s Operating Profit (PBDIT) for this quarter has also been the highest in the last five quarters at Rs 146.61 crore, indicating a positive trend in the near term. The Operating Profit Margin has also been the highest at 22.97%, showing an improvement in the company’s efficiency.

In terms of profitability, FDC has shown a positive trend in its Profit Before Tax less Other Income (PBT) and Profit After Tax (PAT) which have been the highest in the last five quarters at Rs 134.29 crore and Rs 119.04 crore respectively.

The company’s Earnings per Share (EPS) for this quarter have also been the highest in the last five quarters at Rs 7.31, indicating an increase in profitability and higher earnings for shareholders. Overall, FDC has shown a positive financial performance in the quarter ending June 2024, making it a stock to watch out for.